Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

This trial is testing a new antibody-drug conjugate — a targeted treatment that delivers chemotherapy directly to myeloma cancer cells — for patients with multiple myeloma that has returned or stopped responding to treatment. This drug targets a protein called CD38, which is commonly found on myeloma cells. **You may be eligible if...** - You are 18 or older - You have relapsed or refractory multiple myeloma (cancer that returned or no longer responds to treatment) - You have already been treated with at least three different drug types (including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody) - Your disease has measurable signs in blood or urine tests - Your overall health status (ECOG score) is 0, 1, or 2 - You are using effective contraception if applicable **You may NOT be eligible if...** - You have active plasma cell leukemia, amyloidosis, or myeloma in the central nervous system - You have POEMS syndrome or spinal cord compression - You received certain prior therapies within the washout period - You are known to be allergic to this drug's ingredients Talk to your doctor to see if this trial is right for you.